Michigan Healthcare Professionals Macomb

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Lung cancer8 trials
• Prostate cancer5 trials
• Head and neck cancer1 trial

Phase

• Phase 38 trials
• Phase 23 trials
• Phase 2/33 trials

Status

• Active, not recruiting11 trials
• Completed1 trial
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• NRG Oncology8 trials
• National Cancer Institute (NCI)6 trials

Running trials

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· NRG Oncology· Source

  Contact: Frank A. Vicini (principal investigator)

• Active, not recruiting

  Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

  NCT05053152· Phase 2· NRG Oncology· Source

• Active, not recruiting

  Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

  NCT05050162· Phase 2/3· NRG Oncology· Source

• Active, not recruiting

  Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

  NCT05050084· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  NCT04513717· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

  NCT04214262· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

  NCT04334941· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

  NCT04092283· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

  NCT03811002· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

  NCT03793179· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

  NCT03367702· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

  NCT03070886· Phase 2/3· NRG Oncology· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Closed trials

• Terminated

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009· Phase 2/3· NRG Oncology· Source